CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe

DE Gilham, Reno Debets, M Pule, RE Hawkins, H Abken

Research output: Contribution to journalArticleAcademicpeer-review

149 Citations (Scopus)


Recent reports on the impressive efficacy of adoptively transferred T cells to challenge cancer in early phase clinical trials have significantly raised the profile of T cell therapy. Concomitantly, general expectations are also raised by these reports, with the natural aspiration to deliver this therapy over a wide range of tumor indications. Chimeric antigen receptors (CARs) endow T cell populations with defined antigen specificities that function independently of the natural T cell receptor and permit targeting of T cells towards virtually any tumor. Here, we review the current clinical application of CAR T cells and relate clinical efficacy and safety of CAR T cell trials to parameters considered critical for CAR engineering, classified as the three T's of CAR T cell manipulation.
Original languageUndefined/Unknown
Pages (from-to)377-384
Number of pages8
JournalTrends in Molecular Medicine
Issue number7
Publication statusPublished - 2012

Cite this